Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Treasury Shares (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Treasury Shares for 4 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 38.1% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 38.1% increase, with the full-year FY2025 number at $2.5 million, up 38.1% from a year prior.
  • Treasury Shares was $2.5 million for Q4 2025 at Day One Biopharmaceuticals, down from $2.8 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.0 million in Q2 2025 to a low of $47400.0 in Q4 2022.
  • A 4-year average of $1.4 million and a median of $1.4 million in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: tumbled 78.59% in 2023, then skyrocketed 1923.86% in 2024.
  • Day One Biopharmaceuticals' Treasury Shares stood at $47400.0 in 2022, then surged by 1902.89% to $949370.0 in 2023, then surged by 86.89% to $1.8 million in 2024, then surged by 38.1% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Treasury Shares are $2.5 million (Q4 2025), $2.8 million (Q3 2025), and $3.0 million (Q2 2025).